177 related articles for article (PubMed ID: 24403492)
1. Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.
Braicu EI; Gasimli K; Richter R; Nassir M; Kümmel S; Blohmer JU; Yalcinkaya I; Chekerov R; Ignat I; Ionescu A; Mentze M; Fotopoulou C; Pop C; Lichtenegger W; Sehouli J; ;
Anticancer Res; 2014 Jan; 34(1):385-91. PubMed ID: 24403492
[TBL] [Abstract][Full Text] [Related]
2. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
Braicu EI; Fotopoulou C; Chekerov R; Richter R; Blohmer J; Kümmel S; Stamatian F; Yalcinkaya I; Mentze M; Lichtenegger W; Sehouli J
Cytokine; 2013 Mar; 61(3):755-8. PubMed ID: 23415672
[TBL] [Abstract][Full Text] [Related]
3. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
4. Altered pattern of circulating matrix metalloproteinases -2,- 9 and tissue inhibitor of metalloproteinase-2 in patients with HCV-related chronic hepatitis. Relationship to histological features.
Bruno CM; Valenti M; Bertino G; Ardiri A; Consolo M; Mazzarino CM; Amoroso A; Neri S
Panminerva Med; 2009 Dec; 51(4):191-6. PubMed ID: 20195229
[TBL] [Abstract][Full Text] [Related]
5. Ten-year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy.
Hwang YY; Moon H; Cho SH; Kim KT; Moon YJ; Kim SR; Kim DS
Gynecol Oncol; 2001 Jul; 82(1):88-93. PubMed ID: 11426967
[TBL] [Abstract][Full Text] [Related]
6. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer.
Wieczorek E; Jablonowski Z; Tomasik B; Konecki T; Jablonska E; Gromadzinska J; Fendler W; Sosnowski M; Wasowicz W; Reszka E
Clin Biochem; 2015 Dec; 48(18):1235-40. PubMed ID: 26197083
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
Lim A; Sia S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin 7 as a predictive factor for response to concommitant radiochemotherapy for locally advanced cervical cancer: a preliminary study.
Lambaudie E; Chereau E; Pouget N; Thomassin J; Minsat M; Charafe-Jauffret E; Jacquemier J; Houvenaeghel G
Anticancer Res; 2014 Jan; 34(1):177-81. PubMed ID: 24403459
[TBL] [Abstract][Full Text] [Related]
9. The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer.
Chereau E; DE LA Hosseraye C; Ballester M; Monnier L; Rouzier R; Touboul E; Daraï E
Anticancer Res; 2013 Apr; 33(4):1661-6. PubMed ID: 23564812
[TBL] [Abstract][Full Text] [Related]
10. Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.
Sidorkiewicz I; Piskór B; Dąbrowska E; Guzińska-Ustymowicz K; Pryczynicz A; Zbucka-Krętowska M; Ławicki S
Anticancer Res; 2019 Nov; 39(11):6403-6412. PubMed ID: 31704874
[TBL] [Abstract][Full Text] [Related]
11. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
12. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
13. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
[TBL] [Abstract][Full Text] [Related]
14. Biological markers and prognosis in recurrent oral cancer after salvage surgery.
Agra IM; Carvalho AL; Pinto CA; Martins EP; Filho JG; Soares FA; Kowalski LP
Arch Otolaryngol Head Neck Surg; 2008 Jul; 134(7):743-9. PubMed ID: 18645125
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.
Sehouli J; Runnebaum IB; Fotopoulou C; Blohmer U; Belau A; Leber H; Hanker LC; Hartmann W; Richter R; Keyver-Paik MD; Oberhoff C; Heinrich G; du Bois A; Olbrich C; Simon E; Friese K; Kimmig R; Boehmer D; Lichtenegger W; Kuemmel S
Ann Oncol; 2012 Sep; 23(9):2259-2264. PubMed ID: 22357252
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation.
Muallem MZ; Marnitz S; Richter R; Köhler C; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):401-6. PubMed ID: 24403494
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
[TBL] [Abstract][Full Text] [Related]
18. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.
Mitsuhashi A; Suzuka K; Yamazawa K; Matsui H; Seki K; Sekiya S
Cancer; 2005 Feb; 103(4):724-30. PubMed ID: 15637689
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study.
Pietruszewska W; Bojanowska-Poźniak K; Kobos J
Otolaryngol Pol; 2016 Jun; 70(3):32-43. PubMed ID: 27386931
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study.
Lee TS; Kang SB; Kim YT; Park BJ; Kim YM; Lee JM; Kim SM; Kim YT; Kim JH; Kim KT
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):304-10. PubMed ID: 23642625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
